# Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®

> **NCT00488371** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 250 (—)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** Pneumococcal Conjugated Vaccine (Prevnar®)

## Key facts

- **NCT ID:** NCT00488371
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 250 (—)
- **Last updated:** 2007-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488371, "Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00488371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*